Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A proof of concept study of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.

Next Previous
Trial Profile

A proof of concept study of TNX-1900 (intranasal potentiated oxytocin) on capsaicin- or electrical stimulation-induced forehead dermal blood flow in healthy female human volunteers.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Oxytocin (Primary)
  • Indications Binge-eating disorder; Diabetes mellitus; Glucose intolerance; Insulin resistance; Migraine; Obesity; Pain; Prader-Willi syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Tonix Pharmaceuticals Holding Corp

Most Recent Events

  • 26 Mar 2026 Status changed from planning to recruiting.
  • 26 Mar 2026 According to Tonix Pharmaceuticals media release, company announced that the first participant has been dosed in this trial.
  • 31 May 2023 According to a Tonix Pharmaceuticals media release, TNX-2900 has been granted Orphan Drug designation by the FDA.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top